Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide.

The development of dendritic cell vaccine-based immunotherapies for glioblastoma. Semin Immunopathol (2017) 0.82

Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma. Cancer Immunol Immunother (2016) 0.75

Dendritic cell vaccines: A review of recent developments and their potential pediatric application. Hum Vaccin Immunother (2016) 0.75

Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. Clin Cancer Res (2017) 0.75

Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood (2009) 2.79

Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med (2000) 2.23

Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clin Cancer Res (2011) 2.15

Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res (1999) 2.02

Cytomegalovirus and brain tumor: epidemiology, biology and therapeutic aspects. Curr Opin Oncol (2013) 1.69

Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med (2008) 1.48

The detection of CMV pp65 and IE1 in glioblastoma multiforme. J Neurooncol (2010) 1.28

Alveolar proteinosis syndrome: pathogenesis, diagnosis, and management. Curr Opin Pulm Med (2009) 1.22

Delayed drug hypersensitivity reactions - new concepts. Clin Exp Allergy (2007) 1.15

Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas. Cancer (1992) 1.12

Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins. Clin Vaccine Immunol (2007) 1.08

Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells. Clin Cancer Res (2014) 1.05

Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. J Immunother (2012) 1.04

Immunotherapy approaches for malignant glioma from 2007 to 2009. Curr Neurol Neurosci Rep (2010) 1.04

Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. Int Rev Immunol (2011) 1.01

Toward effective immunotherapy for the treatment of malignant brain tumors. Neurotherapeutics (2009) 1.00

Testing for drug hypersensitivity syndromes. Clin Biochem Rev (2013) 1.00

Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF. Mol Ther (2011) 0.98

Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. Future Oncol (2013) 0.97

Drug eruptions: approaching the diagnosis of drug-induced skin diseases. J Drugs Dermatol (2003) 0.80

Granulocyte-macrophage colony-stimulating factor increases the proportion of circulating dendritic cells after autologous but not after allogeneic hematopoietic stem cell transplantation. Cytotherapy (2011) 0.79

Effective acute desensitization for immediate-type hypersensitivity to human granulocyte-monocyte colony stimulating factor. Ann Allergy Asthma Immunol (1999) 0.78

Hypersensitivity reactions to Escherichia coli-derived polyethylene glycolated-asparaginase associated with subsequent immediate skin test reactivity to E. coli-derived granulocyte colony-stimulating factor. J Allergy Clin Immunol (1998) 0.78